

PRESS RELEASE | Les Ulis, FRANCE - June 19, 2025

CELLforCURE by SEQENS to Manufacture Galapagos' CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region

CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos' CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed/refractory non-Hodgkin lymphoma (NHL) indications. The collaboration could be broadened to include the manufacturing of additional product candidates in Galapagos' portfolio.

CELLforCURE by SEQENS' state-of-the-art commercial cell therapy manufacturing facility in Les Ulis, France, will play a key role in supporting Galapagos' upcoming trials in Paris and the broader France area.

Galapagos' Cell Therapy Manufacturing Platform

Galapagos' innovative decentralized manufacturing platform for cell therapies is designed to be deployed close to cancer treatment centers. By bringing the manufacturing process closer to patients, Galapagos' platform is designed to deliver fresh, fit, stem-like early memory cell therapy with a median vein-to-vein time of seven days, thereby avoiding cryopreservation and eliminating the need for cytotoxic bridging therapy.

Strategic Choice of CELLforCURE by SEQENS

The selection of CELLforCURE by SEQENS as a manufacturing partner is based on CELLforCURE's proven expertise in GMP-compliant commercial-scale cell therapy production. As a recognized player in France, CELLforCURE by SEQENS has worked closely with French hospitals for over five years, actively contributing to the establishment of the first local CAR-T manufacturing pathways in the European Union.

With its strategic location in Les Ulis, near major treatment centers in Paris and the broader France area, CELLforCURE by SEQENS enables Galapagos to realize its ambition of a decentralized manufacturing network bringing treatments closer to patients for faster and more efficient access to care.

Harnessing Innovation and Experience to Deliver Cell Therapies

"We are proud and honored to support Galapagos at this pivotal stage of development for GLPG5101" said Marc-Olivier Mignon, President of CELLforCURE by SEQENS. "Our expertise in advanced therapy manufacturing at clinical and commercial stage will support the integration of disruptive cutting-edge technologies as well as the release of a fresh, early-memory-enriched cell therapy."

About CELLforCURE by SEQENS and SEQENS:

CELLforCURE SAS (commercial name: CELLforCURE by SEQENS) is a CDMO authorized by ANSM (French Regulatory Authority), dedicated to ATMPs production from concept to commercialization. With

advanced technologies, extensive capabilities, and large-scale capacity, CELLforCURE by SEQENS offers a seamless journey from early-stage development to commercial manufacturing of a wide range of cell therapies.

SEQENS Group is a global partner in health, personal care and specialty ingredients, leveraging 3300 employees, 16 manufacturing sites and 9 R&D centers in 9 countries.

press@seqens.com / cellandgene.seqens.com / LinkedIn: [CELLforCURE by SEQENS](#)

About Galapagos:

Galapagos is a biotechnology company with operations in the U.S., Europe, and Asia dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life. Focusing on high unmet medical needs, Galapagos synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class medicines. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, Galapagos is committed to challenging the status quo and delivering results for patients, its employees, and its shareholders. Galapagos' goal is to meet current medical needs and to anticipate and shape the future of healthcare, ensuring that its innovations reach those who need them most. For additional information, please visit www.glp.com or follow the Company on [LinkedIn](#) or [X](#).